Clinical Research Foundation Inc
- Assets
- $267.2k
- Revenue
- $628.0k
- Investments
- $0.0
- Employees
- 12
- Location
- Louisville, KY
- Founding
- 05/1991
- Data as of
- 12/2021
- EIN
- 61-1144514
Organization Overview
Clinical Research Foundation Inc is located in Louisville, KY. The organization was established in 1991. As of 12/2021, Clinical Research Foundation Inc employed 12 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Clinical Research Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Clinical Research Foundation Inc generated $628.0k in total revenue. The organization has seen a slow decline revenue. Over the past 7 years, revenues have fallen by an average of (1.7%) each year. All expenses for the organization totaled $599.8k during the year ending 12/2021. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
CLINICAL RESEARCH FOUNDATION, INC. (CRF) PROMOTES QUALITY SCIENTIFIC RESEARCH TO IMPROVE THE MEDICAL TREATMENT, GENRAL HEALTH AND QUALITY OF LIFE FOR OUR NATIONS VETERANS BY PROVIDING A FLEXIBLE FUNDING MECHANISM TO ROBLEY REX VA MEDICAL CENTER RESEARCHERS FOR NON-VA FUNDED STUDIES OR TRIALS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
INFECTIOUS DISEASE PROGRAM - 109,918 PI: RAMIREZ, JULIO, MD, ARNOLD, FOREST, MD & BURNS, MARK, MD (RAMIR, BURCLO) INFECTIOUS DISEASES ARE DISORDERS CAUSED BY ORGANISMS SUCH AS BACTERIA, VIRUSES, FUNGI OR PARASITES AND A SOURCE OF SIGNIFICANT ILLNESS IN THE VETERAN POPULATION. THE PURPOSE OF THESE STUDIES WAS TO PROVIDE THE LOUISVILLE VA MEDICAL CENTER A BETTER UNDERSTANDING OF THE SIGNIFICANCE OF STREPTOCOCCAL PNEUMONIA IN THEIR PATIENT POPULATION. SPECIFICALLY, THE STUDY WILL ESTIMATE THE PORTION OF RADIO-GRAPHICALLY CONFIRMED COMMUNITY- ACQUIRED PNEUMONIA (CAP) IN ADULTS AGED 18 YEARS AND OLDER WHICH IS DUE TO STREPTOCOCCUS PNEUMONIA AND TO ESTIMATE THE DISTRIBUTION OF 13 DIFFERENT S. PNEUMONIA SEROTYPES IN THIS POPULATION. THIS WILL HELP DETERMINE EARLY AND LATE IMPROVEMENTS OR POSSIBLE COMPLICATIONS AND THEIR FREQUENCY IN HOSPITALIZED ADULT PATIENTS WITH PNEUMONIA TO ADDRESS SOME OF THE GAPS IN CURRENT KNOWLEDGE. ADDITIONAL WORK IS BEING DONE TO TEST THE EFFICACY OF THE PFIZER COVID-19 VACCINE.
DIABETES & CARDIOVASCULAR DISEASE PROGRAM - 92,610 PI: KRISHNASAMY, SATHYA, MD (KRISPREV,KRISPROM, KRISSEL & KRISSOUL) DIABETES AND RELATED CARDIOVASCULAR DISEASES ARE A MAJOR CAUSE OF MORBIDITY AND MORTALITY AMONG VETERANS. THE PROMINENT STUDY (KRISPROM) IS TARGETED TO REDUCE CARDIOVASCULAR EVENTS BY REDUCING TRIGLYCERIDES IN DIABETIC VETERANS THROUGH TREATMENT WITH PEMAFIBRATE. THE SELECT STUDY IS DESIGNED TO MEASURE THE EFFECTS ON CARDIOVASCULAR OUTCOMES IN OVERWEIGHT OR OBESE VETERANS. THE SOUL STUDY IS TO DEMONSTRATE THAT ORAL SEMAGLUTIDE LOWERS THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS COMPARED TO PLACEBO, BOTH ADDED TO STANDARD CARE IN PATIENTS WITH TYPE 2 DIABETES AND AT HIGH RISK OF CARDIOVASCULAR EVENTS. THE PREVENTABLE STUDY IS A STUDY EVALUATING THE EVENTS AND BENEFITS OF LIPID LOWERING IN OLDER ADULTS.
GASTROINTESTINAL DISEASE PROGRAM - 35,519 PI: DRYDEN, GERALD, MD, PHD (DRYVIV, DRYCARP) PI: OMER, ENDASHAW, MD (OMCOMM, OMECLIP, OMGAL, OMINSP) GASTROINTESTINAL DISEASES (ABBREV. GI DISEASES OR GI ILLNESSES) REFER TO DISEASES INVOLVING THE GASTROINTESTINAL TRACT. GI DISEASES AND ILLNESSES HAVE A SIGNIFICANT IMPACT ON THE VETERAN POPULATION. THE PURPOSE OF VIVID (DRYVIV) IS TO EVALUATE THE SAFETY AND EFFICACY OF MIRIKIZUMAB IN ACHIEVING ENDOSCOPIC AND CLINICAL OUTCOMES UP TO WEEK 52 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. THE CARPO (DRYCARP) STUDY IS TESTING AUXORA IN PATIENTS WITH ACUTE PANCREATITIS AND ACCOMPANYING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. COMMAND & INSPIRE (OMCOMM, OMINSP) IS STUDYING THE SAFETY AND EFFICACY OF RISANKIZUMAB IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS. ECLIPSE (OMECLIP) IS EVALUATING A CTDNA ASSAY TO SCREEN FOR MALIGNANT DISEASE. GALAXI (OMGAL) IS EVALUATING THE EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE.
THE ORGANIZATION OPERATES SEVERAL CLINICAL TRIALS FOR A VARIETY OF HEALTH ISSUES THAT INPACT OUR VETERANS.
INFECTIOUS DISEASE PROGRAM - 109,918 PI: RAMIREZ, JULIO, MD, ARNOLD, FOREST, MD & BURNS, MARK, MD (RAMIR, BURCLO) INFECTIOUS DISEASES ARE DISORDERS CAUSED BY ORGANISMS SUCH AS BACTERIA, VIRUSES, FUNGI OR PARASITES AND A SOURCE OF SIGNIFICANT ILLNESS IN THE VETERAN POPULATION. THE PURPOSE OF THESE STUDIES WAS TO PROVIDE THE LOUISVILLE VA MEDICAL CENTER A BETTER UNDERSTANDING OF THE SIGNIFICANCE OF STREPTOCOCCAL PNEUMONIA IN THEIR PATIENT POPULATION. SPECIFICALLY, THE STUDY WILL ESTIMATE THE PORTION OF RADIO-GRAPHICALLY CONFIRMED COMMUNITY- ACQUIRED PNEUMONIA (CAP) IN ADULTS AGED 18 YEARS AND OLDER WHICH IS DUE TO STREPTOCOCCUS PNEUMONIA AND TO ESTIMATE THE DISTRIBUTION OF 13 DIFFERENT S. PNEUMONIA SEROTYPES IN THIS POPULATION. THIS WILL HELP DETERMINE EARLY AND LATE IMPROVEMENTS OR POSSIBLE COMPLICATIONS AND THEIR FREQUENCY IN HOSPITALIZED ADULT PATIENTS WITH PNEUMONIA TO ADDRESS SOME OF THE GAPS IN CURRENT KNOWLEDGE. ADDITIONAL WORK IS BEING DONE TO TEST THE EFFICACY OF THE PFIZER COVID-19 VACCINE.
DIABETES & CARDIOVASCULAR DISEASE PROGRAM - 92,610 PI: KRISHNASAMY, SATHYA, MD (KRISPREV,KRISPROM, KRISSEL & KRISSOUL) DIABETES AND RELATED CARDIOVASCULAR DISEASES ARE A MAJOR CAUSE OF MORBIDITY AND MORTALITY AMONG VETERANS. THE PROMINENT STUDY (KRISPROM) IS TARGETED TO REDUCE CARDIOVASCULAR EVENTS BY REDUCING TRIGLYCERIDES IN DIABETIC VETERANS THROUGH TREATMENT WITH PEMAFIBRATE. THE SELECT STUDY IS DESIGNED TO MEASURE THE EFFECTS ON CARDIOVASCULAR OUTCOMES IN OVERWEIGHT OR OBESE VETERANS. THE SOUL STUDY IS TO DEMONSTRATE THAT ORAL SEMAGLUTIDE LOWERS THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS COMPARED TO PLACEBO, BOTH ADDED TO STANDARD CARE IN PATIENTS WITH TYPE 2 DIABETES AND AT HIGH RISK OF CARDIOVASCULAR EVENTS. THE PREVENTABLE STUDY IS A STUDY EVALUATING THE EVENTS AND BENEFITS OF LIPID LOWERING IN OLDER ADULTS.
GASTROINTESTINAL DISEASE PROGRAM - 35,519 PI: DRYDEN, GERALD, MD, PHD (DRYVIV, DRYCARP) PI: OMER, ENDASHAW, MD (OMCOMM, OMECLIP, OMGAL, OMINSP) GASTROINTESTINAL DISEASES (ABBREV. GI DISEASES OR GI ILLNESSES) REFER TO DISEASES INVOLVING THE GASTROINTESTINAL TRACT. GI DISEASES AND ILLNESSES HAVE A SIGNIFICANT IMPACT ON THE VETERAN POPULATION. THE PURPOSE OF VIVID (DRYVIV) IS TO EVALUATE THE SAFETY AND EFFICACY OF MIRIKIZUMAB IN ACHIEVING ENDOSCOPIC AND CLINICAL OUTCOMES UP TO WEEK 52 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. THE CARPO (DRYCARP) STUDY IS TESTING AUXORA IN PATIENTS WITH ACUTE PANCREATITIS AND ACCOMPANYING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME. COMMAND & INSPIRE (OMCOMM, OMINSP) IS STUDYING THE SAFETY AND EFFICACY OF RISANKIZUMAB IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS. ECLIPSE (OMECLIP) IS EVALUATING A CTDNA ASSAY TO SCREEN FOR MALIGNANT DISEASE. GALAXI (OMGAL) IS EVALUATING THE EFFICACY OF GUSELKUMAB IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE.
THE ORGANIZATION OPERATES SEVERAL CLINICAL TRIALS FOR A VARIETY OF HEALTH ISSUES THAT INPACT OUR VETERANS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Michael Book PHD Executive Di | Officer | 24 | $42,500 |
Gerald Dryden MD PHD Chair | OfficerTrustee | 2 | $0 |
Greg Bethards Director | Trustee | 1 | $0 |
Belinda Setters MD Director | Trustee | 1 | $0 |
Paul Sklena MD Statutory Di | Trustee | 1 | $0 |
Sathya Krishnasamy MD Director | Trustee | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $33,430 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $33,430 |
| Total Program Service Revenue | $628,010 |
| Investment income | $20 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $628,030 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $42,500 |
| Compensation of current officers, directors, key employees. | $15,300 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $192,483 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $18,329 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $9,000 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $3,364 |
| Advertising and promotion | $0 |
| Office expenses | $1,195 |
| Information technology | $111 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $125 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $2,515 |
| All other expenses | $11,424 |
| Total functional expenses | $599,758 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $173,278 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $88,074 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $5,375 |
| Prepaid expenses and deferred charges | $463 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $267,190 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $267,190 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $267,190 |
Grants Recieved
Over the last fiscal year, we have identified 2 grants that Clinical Research Foundation Inc has recieved totaling $100,000.
| Awarding Organization | Amount |
|---|---|
University Of Louisville Research Foundation Inc Louisville, KY PURPOSE: Research Support | $50,000 |
University Of Louisville Research Foundation Inc Louisville, KY PURPOSE: Research Support | $50,000 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Gateway For Cancer Research Inc Schaumburg, IL | $18,916,146 | $4,888,015 |
Center For Dialysis Care At Heather Hills Shaker Heights, OH | $881,734 | $1,604,390 |
Indiana Institute For Medical Research Inc Indianapolis, IN | $2,711,887 | $1,140,954 |
Society For Cardiovascular Chicago, IL | $1,623,146 | $1,181,664 |
Clinical Research Foundation Inc Louisville, KY | $267,190 | $628,030 |
Cryptic Masons Medical Research Foundation Inc Brownsburg, IN | $5,269,726 | $1,168,505 |
Abraham S Ende Research Foundation Inc Petersburg, VA | $10,425 | $0 |